NASDAQ : EQ

Equillium, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.42 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 111.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Details

NameEquillium, Inc.
SectorHealthcare
IndustryBiotechnology
Employees15
Founded2017
Ipo Date2018-10-11
CeoBruce Steel
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS29446K1060
Cusip29446K106
Cik0001746466
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Bruce SteelCo-Founder, Chief Executive Officer and Director
Dr. Stephen Connelly Ph.D.Chief Scientific Officer and President
Christine Zedelmayer M.B.A., P.M.P.Senior Vice President and Chief Operating Officer
Penny Tom CPASenior Vice President of Finance and Principal Accounting Officer
Michael MooreVice President of Investor Relations and Corporate Communications
Snehal Naik Ph.D.Chief Development Officer
Dr. Lisette AcevedoVice President of Clinical Development

Contact

Address2223 Avenida De La Playa, Suite 105, La Jolla, California 92037, United States
Phone858 240 1200
Websitehttps://www.equilliumbio.com